We have previously shown that selective inhibition of histone deacetylase 3 (HDAC3) decreases infarct volume and improves long-term functional outcomes after stroke. In this study, we examined the effects of HDAC3 inhibition on cerebral edema and blood–brain barrier (BBB) leakage and explored its underlying mechanisms. Adult male Wistar rats were subjected to 2-h middle cerebral artery occlusion (MCAO) and randomly treated i.p. with either vehicle or a selective HDAC3 inhibitor (RGFP966) at 2 and 24 h after stroke. Modified neurological severity scores (mNSS) were calculated at 2 h, 1 day, and 3 days. H&E, Evans blue dye (EBD) assay, and fluorescein isothiocyanate (FITC)-dextran were employed to assess cerebral edema and BBB leakage. Western blot for matrix metalloproteinase-9 (MMP9), MMP-9 zymography, and immunostaining for HDAC3, GFAP, Iba-1, albumin, aquaporin-4, claudin-5, ZO-1, and NF-kB were performed. Early RGFP966 administration decreased cerebral edema (p = 0.002) and BBB leakage, as measured by EBD assay, FITC-dextran, and albumin extravasation (p < 0.01). RGFP966 significantly increased tight junction proteins (claudin-5 and ZO-1) in the peri-infarct area. RGFP966 also significantly decreased HDAC3 in GFAP + astrocytes, which correlated with better mNSS (r = 0.67, p = 0.03) and decreased cerebral edema (r = 0.64, p = 0.04). RGFP966 decreased aquaporin-4 in GFAP + astrocytes (p = 0.002), as well as, the inflammatory markers Iba-1, NF-kB, and MMP9 in the ischemic brain (p < 0.05). Early HDAC3 inhibition decreases cerebral edema and BBB leakage. BBB protection by RGFP966 is mediated in part by the upregulation of tight junction proteins, downregulation of aquaporin-4 and HDAC3 in astrocytes, and decreased neuroinflammation.
Introduction: We have previously shown that selective inhibition of histone deacetylase 3 (HDAC3) decreases infarct volume and improves long-term functional outcomes after stroke. In this study, we examined the effects of HDAC3 inhibition on cerebral edema and blood-brain barrier (BBB) leakage and explored its underlying mechanisms.Methods: Adult male Wistar rats were subjected to 2-h middle cerebral artery occlusion (MCAO) and randomly treated i.p. with either vehicle or a selective HDAC3 inhibitor (RGFP966) at 2 and 24 hours after stroke. Modified neurological severity scores (mNSS) were calculated at 2 hours, 1 day, and 3 days. H&E and Evans blue dye (EBD) assay were employed to assess cerebral edema and BBB leakage, respectively. Western Blot for matrix metalloproteinase-9 (MMP9) and immunostaining for HDAC3, GFAP, Iba-1, albumin, aquaporin-4, claudin-5, ZO-1, and NF-kappa were performed. Results: Early RGFP966 administration decreased cerebral edema (p=0.002) and BBB leakage, as measured by EBD assay and albumin extravasation (p=0.001). RGFP966 significantly increased the expression of tight junction proteins (claudin-5 and ZO-1) in the peri-infarct area. RGFP966 also significantly decreased HDAC3 expression in GFAP+ astrocytes, which correlated with better mNSS (r=0.67, p=0.03) and decreased cerebral edema (r=0.64, p=0.04). RGFP966 decreased the expression of aquaporin-4 in GFAP+ astrocytes (p=0.002), as well as, the inflammatory markers Iba-1, NF-kappa, and MMP9 in the ischemic brain (p<0.05).Conclusions: Early HDAC3 inhibition decreases cerebral edema and BBB leakage. BBB protection by RGFP966 is mediated in part by the upregulation of tight junction proteins, downregulation of aquaporin-4 and HDAC3 in astrocytes, and decreased neuroinflammation.
Introduction: Histone deacetylase 3 (HDAC3) has been implicated as neurotoxic in several neurodegenerative conditions. However, its role in ischemic stroke has not been thoroughly explored. In this study, we examined HDAC3 expression after stroke and tested whether selective inhibition of HDAC3 decreases cerebral edema and blood-brain barrier (BBB) leakage after ischemia. Methods: To examine HDAC3 expression over time, adult male Wistar rats (n=6/group) were subjected to middle cerebral artery occlusion (MCAO) and sacrificed at different time points after stroke. Another set of adult male Wistar rats was subjected to 2-h MCAO, and randomly selected animals were treated i.p. with either vehicle (1% Tween 80) or a selective HDAC3 inhibitor (RGFP966, 10 mg/kg) at 2 and 24 h after MCAO. Behavioral tests were performed, and infarct volumes and cerebral edema were measured. Evans blue dye (EBD) assay was employed to assess BBB leakage. Immunostaining for HDAC3, CD31, claudin-5, occludin, and ZO-1; and Western Blot for TNF-alpha and matrix metalloproteinase-9 (MMP9) were performed. Results: Total and neuronal HDAC3 significantly increased in the peri-infarct cortex as early as 3 hours after ischemia. HDAC3 levels continued to be significantly elevated at 3 days and returned to baseline at 7 days. Selective HDAC3 inhibition improved functional outcome (p=0.01) and reduced infarct volumes (p<0.001). Compared to vehicle control, RGFP966 treatment significantly decreased cerebral edema (p<0.001) as well as BBB leakage, as measured by EBD assay. Immunostaining showed that RGFP966 significantly increased the expression of tight junction proteins (claudin-5, occludin, and ZO-1) in the peri-infarct area compared to vehicle control group. Western Blot showed that RGFP966 treatment significantly decreased the expression of TNF-alpha and MMP9 in the ischemic brain. Conclusions: HDAC3 is upregulated in the ischemic brain as early as 3 hours after stroke. Early administration of a selective HDAC3 inhibitor improves neurological functional outcome and decreases infarct volume, cerebral edema, and BBB leakage. BBB protection by selective inhibition of HDAC3 is mediated in part by upregulation of tight junction proteins and attenuation of TNF-alpha and MMP9.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.